Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Ajinomoto Althea, Inc.
EIR
•Ajinomoto Althea, Inc.•August 7, 2019

Ajinomoto Althea, Inc. – FDA EIR, Aug 7, 2019

Record Details

An FDA for-cause inspection of Ajinomoto Althea, Inc., operating as Ajinomoto Biopharma Services, a sterile injectable drug manufacturer in San Diego, CA, was conducted from July 30 to August 7, 2019. The inspection, carried out under FDA Compliance Programs for drug process and quality systems, followed up on issues from a prior March 2019 inspection that cited inadequate deviation investigation, lack of quality oversight, and insufficient clean hold time studies. This inspection specifically focused on a history of lots exceeding action limits for particles, identified between August 2017 and March 2018, stemming from sources like stainless steel trays, stoppers, capping equipment, and oxidized stainless steel connectors. Despite some corrective actions, a two-item FDA-483 was issued. The main violations included: 1) The Quality Control Unit failing to consistently reject drug product lots associated with faulty connectors and corroded stainless steel particulates. Affected injectable lots were not always rejected, even when linked to a confirmed root cause of corroded components within connection fittings. 2) Investigations into unexplained discrepancies or batch failures, such as the stainless steel particulate issue, did not consistently document the assessment of impact on other batches of the same drug product or other potentially affected drug products, as required by cGMP investigation procedures (21 CFR 211). Ajinomoto Althea's management committed to submitting a written response to the FDA-483 observations within 15 business days. While some prior deficiencies from the March 2019 inspection were corrected, issues related to quality agreements, clean hold time studies, and conveyor airflow visualization remained in progress or partially corrected.

Company
Ajinomoto Althea, Inc.
Inspection date
August 7, 2019
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Ryan Koed (company_representative)
  • J. David Enloe, Jr. (company_representative)
  • Sheila Dentino (company_representative)
  • Kristin M. Defife (recipient)
  • Tim Bourque (company_representative)
View Company Profile

ID · 112ce0ca-fbe9-4c70-8b5c-e856206bb982

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Ajinomoto Althea, Inc.
  • 483 - 2025-05-09May 9, 2025
  • 483 - 2023-09-20September 20, 2023
  • 483 - 2023-02-09February 9, 2023
  • 483 - 2023-01-16January 16, 2023
  • 483 - 2021-05-25May 25, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ajinomoto Althea, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.